Jantar is a clinical R&D company in the field of chronic rhinosinusitis. Its product is a nasal spray of dicholine succinate. Clinical efficacy has been demonstrated by well-documented case studies which showed that the drug relieves all symptoms of the disease. A PCT patent has been filed.
Cooperation possibilities
Jantar is looking for an international license partner for the conduct of a phase III study as basis for market registration and for later commerzialization of the nasal spray.
- https://www.jantar.ch
- +41 79 254 92 86
- Send an email
- Peter Schoch
Some insights
Chronic rhinosinusitis is the second most prevalent chronic inflammatory disease, with still limited treatment options. Dicholine succinate has the potential for a major therapeutic advance. It is based on a novel mechanism free of adverse effects and might provide relief to millions of patients.
Jantar is a one-man R&D company focusing on a nasal spray of dicholine succinate for the treatment of chronic rhinosinusitis. The entire preclinical and clinical development, including proof of clinical efficacy and patenting, was accomplished alone.
Most impressive are companies which build a bridge from the lab to the clinic based on cutting-edge science, imagination and persistence. Examples are Genentech (antibodies), BioNTech (immunotherapies based on mRNA) as well as Actelion and Indorsia (small molecules with novel mechanisms).
By providing a platform to introduce Jantar GmbH to potential investors/partners.
Jantar is seeking an international licensing partner to complete the development of the nasal spray with a phase III trial as the basis for market registration and to commercialize it afterwards. This partner must therefore be interested in a consumer health product for chronic rhinosinusitis.